Letter to the Editor, Re: Cadier et al. (2017)
Chibuzo Iloabuchi, Amanda Stover, Pragya Rai, Yifan Zhang, Khalid M. Kamal – 31 March 2017
Long‐term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years
James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Tan‐To Cheung, Jeff Wing‐Chiu Dai, Sui‐ling Sin, Ka‐Wing Ma, Kelvin Ng, Kevin Tak‐Pan Ng, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen, Chung‐Mau Lo – 31 March 2017 – Long‐term antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation. We determined the long‐term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin.
Assessment of biopsy‐proven liver fibrosis by two‐dimensional shear wave elastography: An individual patient data‐based meta‐analysis
Eva Herrmann, Victor de Lédinghen, Christophe Cassinotto, Winnie C.‐W. Chu, Vivian Y.‐F. Leung, Giovanna Ferraioli, Carlo Filice, Laurent Castera, Valérie Vilgrain, Maxime Ronot, Jérôme Dumortier, Aymeric Guibal, Stanislas Pol, Jonel Trebicka, Christian Jansen, Christian Strassburg, Rongqin Zheng, Jian Zheng, Sven Francque, Thomas Vanwolleghem, Luisa Vonghia, Emanuel K.
Treating hepatitis C viral infection in patients with chronic kidney disease: When and how
Fernando E. Pedraza, Marco A. Ladino Avellaneda, David Roth – 30 March 2017
Causality assessment for liver injury attributable to dietary supplements
Elizabeth Zheng, Victor J. Navarro – 30 March 2017
Novel therapies in the management of acute episodes of hepatic encephalopathy
Rajiv Jalan – 30 March 2017
Potential epidemiologic, economic, and budgetary impacts of current rates of hepatitis C treatment in medicare and non‐medicare populations
John Wittenborn, Joanne Brady, Michelle Dougherty, David Rein – 30 March 2017 – We forecast the health and budgetary impact of hepatitis C (HCV) treatment on the Medicare program based on currently observed rates of treatment among Medicare and non‐Medicare patients and identify the impact of higher rates of treatment among non‐Medicare populations.
Unexpected viral relapses in hepatitis C virus–infected patients diagnosed with hepatocellular carcinoma during treatment with direct‐acting antivirals
Alessandro Soria, Massimiliano Fabbiani, Giuseppe Lapadula, Andrea Gori – 30 March 2017
Grading the range of hepatic encephalopathy from overt to covert: Animals to the rescue!
German Soriano, Jasmohan S. Bajaj – 30 March 2017